166 related articles for article (PubMed ID: 16166986)
1. Farnesyltransferase inhibitors.
Kurzrock R
Clin Adv Hematol Oncol; 2005 Mar; 3(3):161-2. PubMed ID: 16166986
[No Abstract] [Full Text] [Related]
2. Farnesyltransferase inhibitor as anticancer agent.
Agrawal AG; Somani RR
Mini Rev Med Chem; 2009 Jun; 9(6):638-52. PubMed ID: 19519490
[TBL] [Abstract][Full Text] [Related]
3. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
4. Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
Oliff A
Biochim Biophys Acta; 1999 May; 1423(3):C19-30. PubMed ID: 10382537
[No Abstract] [Full Text] [Related]
5. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.
Klochkov SG; Neganova ME; Yarla NS; Parvathaneni M; Sharma B; Tarasov VV; Barreto G; Bachurin SO; Ashraf GM; Aliev G
Semin Cancer Biol; 2019 Jun; 56():128-134. PubMed ID: 29100957
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitors: where are we now?
Tsimberidou AM; Chandhasin C; Kurzrock R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1569-80. PubMed ID: 21083522
[TBL] [Abstract][Full Text] [Related]
7. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Baum C; Kirschmeier P
Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
10. Tipifarnib in acute myeloid leukemia.
Burnett AK; Kell J
Drugs Today (Barc); 2007 Nov; 43(11):795-800. PubMed ID: 18174965
[TBL] [Abstract][Full Text] [Related]
11. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
Zhang M; Jiang D
Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors.
Hahn SM; Bernhard E; McKenna WG
Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Adjei AA
Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
[No Abstract] [Full Text] [Related]
14. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
Gotlib J
Curr Hematol Rep; 2005 Jan; 4(1):77-84. PubMed ID: 15610664
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
de Bono JS; Tolcher AW; Rowinsky EK
Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
[TBL] [Abstract][Full Text] [Related]
16. [Development of farnesyltransferase inhibitor for anti-cancer drugs].
Takemoto Y; Imoto M
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1713-8. PubMed ID: 18051405
[No Abstract] [Full Text] [Related]
17. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Malik SN; Bedolla RG; Hidalgo M; Brattain MG; Kreisberg JI
Methods Mol Med; 2003; 85():135-40. PubMed ID: 12710204
[No Abstract] [Full Text] [Related]
18. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
[TBL] [Abstract][Full Text] [Related]
20. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
Blum R; Kloog Y
Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
